Comments Off on Alnylam Completes Enrollment in ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias (AHPs)
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aug. 21, 2018– Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY),
We and our partners use cookies on this site to improve our service, perform analytics, personalize advertising, measure advertising performance, and remember website preferences.Ok